XORTX extends deadline to complete Vectus acquisition to March

XORTX Therapeutics Inc. (NASDAQ: XRTX) has extended the deadline to complete its acquisition of a renal anti-fibrotic therapeutic program from Vectus Biosystems Limited to March 31, 2026.

The pharmaceutical company originally entered into a term sheet on October 17, 2025, to acquire VB4-P5, a chemical entity designed to treat kidney fibrosis, along with associated intellectual property, regulatory documentation, and manufacturing data. The initial agreement provided for closing within 90 days of execution.

The extension agreement allows additional time for intellectual property transfer. The acquisition remains subject to finalization of closing documentation, regulatory approvals, and compliance with stock exchange requirements and securities laws.

XORTX also announced it has scheduled its Annual and Special Meeting of Shareholders for March 24, 2026. Shareholders of record on February 20, 2026, will be entitled to vote at the meeting.

The company granted 20,000 stock options to newly appointed board member Krysta Davies Foss. The options carry an exercise price of CAD $0.69 and expire in five years.

VB4-P5 is designed to inhibit kidney fibrosis, a condition affecting an estimated 14% of adults globally. The program includes patent protection across more than 30 global jurisdictions with composition-of-matter and method-of-use claims.

XORTX develops treatments targeting aberrant purine metabolism and xanthine oxidase to reduce uric acid production. The company's pipeline includes XRx-026 for gout treatment, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney injury associated with respiratory virus infections.

You May Also Be Interested In

• Kevin Knight retires from Knight-Swift Transportation
• Walmart adds Subway delivery through its app in six states
• Generation Income Properties adds three directors, targets data centers